• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.

作者信息

Chott A, Gisslinger H, Thiele J, Fritz E, Linkesch W, Radaszkiewicz T, Ludwig H

机构信息

Department of Pathology, University of Vienna, Austria.

出版信息

Br J Haematol. 1990 Jan;74(1):10-6. doi: 10.1111/j.1365-2141.1990.tb02531.x.

DOI:10.1111/j.1365-2141.1990.tb02531.x
PMID:2310690
Abstract

Interferon(rIFN)-alpha, a successful therapeutic agent in the control of thrombocytosis, has been shown to suppress human megakaryopoiesis. We investigated bone marrow biopsies from 12 patients with thrombocytosis due to chronic myeloproliferative disorders. Prior to treatment as well as during rIFN-alpha-2c therapy, several morphometric parameters of megakaryopoiesis were evaluated. Megakaryocyte density decreased significantly in all patients, megakaryocyte size decreased in polycythaemia vera, agnogenic myeloid metaplasia, and essential thrombocythaemia, but increased in chronic myeloid leukaemia. The various changes observed during therapy indicate an inhibitory effect of rIFN-alpha-2c on megakaryopoiesis and suggest a selective influence on megakaryocytes at various stages of maturation. Increased numbers of pyknotic (bare) nuclei may reflect a shortening of megakaryocyte life-span. No remarkable changes were found in the fibre content of the bone marrow.

摘要

相似文献

1
Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
Br J Haematol. 1990 Jan;74(1):10-6. doi: 10.1111/j.1365-2141.1990.tb02531.x.
2
Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.伴有血小板增多症的慢性骨髓增殖性疾病骨髓活检的组织形态计量学——对原发性(特发性)血小板增多症诊断具有重要意义的特征
Virchows Arch A Pathol Anat Histopathol. 1988;413(5):407-17. doi: 10.1007/BF00716989.
3
Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.干扰素α-2b治疗伴有血小板增多症的费城染色体阴性慢性骨髓增殖性疾病
Br J Haematol. 1989 Jun;72(2):173-7. doi: 10.1111/j.1365-2141.1989.tb07679.x.
4
Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.慢性骨髓增殖性疾病中的巨核细胞生成。一项形态学评估,特别关注原发性血小板增多症。
Anal Quant Cytol. 1984 Sep;6(3):155-67.
5
[Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].[骨髓增殖性疾病过程中血小板增多症患者巨核细胞中的血细胞入胞现象]
Acta Haematol Pol. 1995;26(2):179-83.
6
Pulmonary fibrosis with megakaryocyte infiltration in agnogenic myeloid metaplasia with thrombocytosis.原发性骨髓化生伴血小板增多症中的肺纤维化伴巨核细胞浸润。
Eur J Haematol. 1996 Oct;57(4):325-7. doi: 10.1111/j.1600-0609.1996.tb01385.x.
7
Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.用α-2a干扰素治疗骨髓增殖性疾病中的血小板增多症。
Blut. 1989 Jan;58(1):15-9. doi: 10.1007/BF00320230.
8
Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.骨髓增殖性疾病(MPD)的诊断标准:原发性血小板增多症、真性红细胞增多症和慢性巨核细胞粒细胞化生。
Neth J Med. 1997 Aug;51(2):57-64. doi: 10.1016/s0300-2977(97)00018-1.
9
Analysis of megakaryocyte ploidy in patients with thrombocytosis.血小板增多症患者巨核细胞倍性分析。
Int J Cell Cloning. 1990 Jul;8(4):299-306. doi: 10.1002/stem.5530080415.
10
Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.干扰素-α可纠正骨髓增殖性疾病患者的血小板增多症。
Cancer Immunol Immunother. 1987;25(3):266-73. doi: 10.1007/BF00199157.

引用本文的文献

1
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?干扰素-α在治疗真性红细胞增多症和相关骨髓增殖性肿瘤中的作用观点:微小残留病和治愈?
Semin Immunopathol. 2019 Jan;41(1):5-19. doi: 10.1007/s00281-018-0700-2. Epub 2018 Sep 10.
2
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).聚乙二醇化干扰素α-2a治疗原发性血小板增多症(ET)和真性红细胞增多症(PV)患者后的组织形态学反应。
Exp Hematol Oncol. 2017 Nov 9;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017.
3
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
真性红细胞增多症患者在使用羟基脲后进行二线细胞减灭治疗该何去何从?
Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14.
4
Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.重组干扰素-α用于治疗骨髓纤维化可减轻骨髓纤维化,改善其形态,并与临床反应相关。
Mod Pathol. 2015 Oct;28(10):1315-23. doi: 10.1038/modpathol.2015.93. Epub 2015 Aug 14.
5
Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.Bcl-xL 抑制剂 ABT-737 联合干扰素 α 治疗特异性靶向 JAK2V617F 阳性真性红细胞增多症造血祖细胞。
Blood. 2010 Nov 18;116(20):4284-7. doi: 10.1182/blood-2010-04-279125. Epub 2010 Jul 12.
6
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.聚乙二醇干扰素α或甲磺酸伊马替尼治疗真性红细胞增多症的最新进展。
Curr Hematol Malig Rep. 2007 Feb;2(1):43-6. doi: 10.1007/s11899-007-0006-2.
7
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.干扰素-α靶向 JAK2V617F 阳性造血祖细胞,并通过 p38 MAPK 通路发挥作用。
Exp Hematol. 2010 Jun;38(6):472-80. doi: 10.1016/j.exphem.2010.03.005. Epub 2010 Mar 18.
8
Treatment of polycythemia vera with recombinant interferon.
Int J Hematol. 2002 Aug;76 Suppl 2:294-5. doi: 10.1007/BF03165137.
9
Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment.长期α-干扰素治疗中断后原发性血小板增多症持续完全血液学缓解。
Ann Hematol. 1993 May;66(5):245-6. doi: 10.1007/BF01738473.
10
Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders.慢性骨髓增殖性疾病中巨核细胞的核仁组织区
Virchows Arch A Pathol Anat Histopathol. 1992;420(5):441-5. doi: 10.1007/BF01600516.